Premium
Effects of rebamipide, a gastro‐protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double‐blind placebo‐controlled multicentre trial
Author(s) -
Fujioka T.,
Arakawa T.,
Shimoyama T.,
Yoshikawa T.,
Itoh M.,
Asaka M.,
Ishii H.,
Kuwayama H.,
Sato R.,
Kawai S.,
Takemoto T.,
Kobayashi K.
Publication year - 2003
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.18.s1.20.x
Subject(s) - rebamipide , omeprazole , medicine , helicobacter pylori , gastroenterology , placebo , gastric mucosa , inflammation , helicobacter , amoxicillin , stomach , randomized controlled trial , gastritis , antibiotics , pathology , alternative medicine , microbiology and biotechnology , biology
Summary Aims : To investigate the effects of rebamipide on the Helicobacter pylori eradication rate with amoxicillin and omeprazole. The trial also examined its histological effects on gastro‐mucosal inflammation after eradication. Methods : Two hundred and six H. pylori ‐positive patients with active gastric ulcer underwent 8‐week based therapy (OA) consisting of 2‐week amoxicillin with omeprazole and subsequent 6‐week omeprazole. They randomly received either rebamipide (OA‐R) or placebo (OA‐P) for 16 weeks: combined with the OA based therapy, and subsequently for another 8 weeks. Besides eradication rate, inflammatory findings of gastric mucosa after eradication were evaluated histologically. Results : Per Protocol Set analysis showed no significant difference in eradication rate between OA‐R (64.6%; 95% confidence interval, 54.3–75.0%) and OA‐P (67.9%; 95% CI, 57.6–78.3%). Histological findings in the gastric mucosa of the ulcer region, however, indicated a significant improvement ( P = 0.017) in inflammation scores in OA‐R (1.84 ± 0.41) compared with that in OA‐P (2.02 ± 0.39) after 16‐weeks of treatment. This suppressive effect on inflammation was observed even in the OA‐R patients unsuccessfully eradicated. Conclusion : Rebamipide demonstrated a suppressive effect on the persistent and possibly chronic inflammation in the gastric mucosa of the ulcer region after eradication, but the drug did not improve the eradication rate.